AI Article Synopsis
- - The study evaluated how dialysis patients responded to three vs. four doses of the BNT162b2 COVID-19 vaccine, involving 106 participants.
- - After the third dose, patients showed increased antibody levels, which declined but remained higher than before; the fourth dose significantly boosted these antibody levels again.
- - Despite the increased antibody response with four doses, the infection risk among patients remained similar whether they received three or four doses.
Article Abstract
The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (43.4%) received 3 and 4 vaccine doses, respectively. Anti-spike (anti-S) antibody titers significantly increased after the third vaccine dose, followed by a decline, yet still remained higher than all previous measurements. The fourth vaccine dose led to another profound rise in anti-S titers. The absolute increase following the fourth dose correlated with response to the third dose. Infection risk however was similar between patients vaccinated with three or four doses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501772 | PMC |
| http://dx.doi.org/10.1159/000525309 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!